Antineoplastic drugs inducing cardiac and vascular toxicity - An update

Vascul Pharmacol. 2023 Sep 7;153:107223. doi: 10.1016/j.vph.2023.107223. Online ahead of print.ABSTRACTWith the improvement in cancer prognosis due to advances in antitumor therapeutic protocols and new targeted and immunotherapies, we are witnessing a growing increase in survival, however, at the same timeincrease in morbidity among cancer survivors as a consequences of the increased cardiovascular adverse effects of antineoplastic drugs. Common cardiovascular complications of antineoplastic therapies may include cardiac complications such as arrhythmias, myocardial ischemia, left ventricular dysfunction culminating in heart failure as well as vascular complications including arterial hypertension, thromboembolic events, and accelerated atherosclerosis. The toxicity results from the fact that these drugs not only target cancer cells but also affect normal cells within the cardiovascular system. In this article, we review the clinical features and main mechanisms implicated in antineoplastic drug-induced cardiovascular toxicity, including oxidative stress, inflammation, immunothrombosis and growth factors-induced signaling pathways.PMID:37678516 | DOI:10.1016/j.vph.2023.107223
Source: Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research